Clopidogrel Tablet, Film Coated
Product Images NDC 72205-199

Clopidogrel Tablets, USP by Novadoz Pharmaceuticals LLC is a medication that contains 97.875 mg of clopidogrel bisulfate, USP per film-coated tablet, which is equivalent to 75 mg of clopidogrel base. This medication is usually prescribed as 100 (10 x 10) unit-dose tablets. It is important to store this medication in well-closed containers at 25°C (77°F), with excursions allowed between 15° to 30°C (59° to 86°F). Further dosage information can be found in the prescribing information. This medication is for prescription only and should be kept out of reach of children. For more detailed information, consult the Medication Guide available at www.NovadozPharma.com/Products.*

This text contains information about a medication called Clopidogrel, with each tablet containing 75 mg of the active ingredient, bisulfate. The prescription details, along with storage instructions, are provided. Additionally, the manufacturer and distributor details are mentioned, including Novadoz Pharmaceuticals LLC. The dosage, prescribing information, storage conditions, and contact information are also included.*

This is a description regarding Clopidogrel Tablets, USP. Each film-coated tablet contains 87.675 mg of clopidogrel bisulfate, which is equivalent to 75 mg of clopidogrel base. It is recommended to dispense the accompanying Medication Guide to each patient. The usual dosage can be found in the Prescribing Information. The tablets are to be stored at controlled room temperature and kept in a well-closed container. The tablets are issued under the brand NOVADOZ. The manufacturer is MSN Laboratories Private Limited in India and distributed by Novadoz Pharmaceuticals LLC in Piscataway, NJ. Pharmacies can print the Medication Guides from www.novadozpharma.com/products.*

This document contains information about a medicine called Clopidogrel. Each tablet is equivalent to 75 mg of the active ingredient. It advises to keep the medicine in well-chosen containers and provides information on prescribing. The medicine is manufactured by MSN Laboratories Private Limited in India and distributed by Novadoz Pharmaceuticals. More details can be found at NovadozPharma.com. Dosage instructions are available in the prescribing information.*

This content provides information on the effect of co-administering different proton pump inhibitors (PPIs) with clopidogrel, focusing on their impact on the active metabolite area under the curve (AUC). Each PPI (Dexlansoprazole, Lansoprazole, Pantoprazole, Omeprazole) is specified with its respective dosage, and the results are presented as mean and 90% confidence interval. The data includes a change relative to clopidogrel alone.*

This is a comparison table showing the cumulative event rate (%) over time for cardiovascular death, myocardial infarction, and stroke between patients treated with placebo (along with aspirin) and patients treated with clopidogrel (along with aspirin). The table indicates a significant difference in event rates between the two groups with a P-value of 0.00009 after a certain number of months of follow-up. It also mentions that other standard therapies were used as appropriate.*

This text presents data regarding a study comparing the mortality rates between a placebo group and a group taking Clopidogrel. It shows that the Clopidogrel group had fewer deaths compared to the placebo group, indicating a 7% proportional risk reduction with statistical significance (p=0.03). The study was conducted over a 28-day period since randomization.*

This text provides data comparison between Placebo and Clopidogrel in terms of event occurrence percentages. Clopidogrel had a slightly lower event rate compared to placebo. There is also mention of proportional risk reduction for re-infarction or stroke along with statistical significance indicated by p-value. The data seems to be related to a study or clinical trial conducted over a period of up to 28 days post randomization.*

This description is about the cumulative event rate (%) for fatal or non-fatal vascular events over 12, 13, and 24 months of follow-up with the use of clopidogrel.*

This text provides a breakdown of the number of patients in certain health conditions and the percentage using Clopidogrel and Aspirin. Data on strokes, M, and PAD are represented with specific numbers for each condition. The table indicates the number of patients favoring Clopidogrel and Aspirin. Additionally, there is a summary for all conditions combined showing percentages for Clopidogrel and Aspirin. The text mentions "Hazard Ratio" with missing specific values.*